228 related articles for article (PubMed ID: 34151860)
1. Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients.
Youssef P; Kim WS; Halliday GM; Lewis SJG; Dzamko N
J Parkinsons Dis; 2021; 11(4):1761-1772. PubMed ID: 34151860
[TBL] [Abstract][Full Text] [Related]
2. Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease.
Lasseter HC; Provost AC; Chaby LE; Daskalakis NP; Haas M; Jeromin A
Cytokine X; 2020 Jun; 2(2):100027. PubMed ID: 33604555
[TBL] [Abstract][Full Text] [Related]
3. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
[TBL] [Abstract][Full Text] [Related]
4. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
Chung CC; Chan L; Chen JH; Hung YC; Hong CT
Biomolecules; 2021 May; 11(5):. PubMed ID: 34067663
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease.
Zou J; Guo Y; Wei L; Yu F; Yu B; Xu A
Neurotherapeutics; 2020 Jul; 17(3):1104-1119. PubMed ID: 32236821
[TBL] [Abstract][Full Text] [Related]
6. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients.
Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH
J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560
[TBL] [Abstract][Full Text] [Related]
7. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
Chen CH; Lee BC; Lin CH
J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
[TBL] [Abstract][Full Text] [Related]
8. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.
Yang SY; Chiu MJ; Lin CH; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH
J Nanobiotechnology; 2016 Jun; 14(1):41. PubMed ID: 27278241
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease.
Foulds PG; Diggle P; Mitchell JD; Parker A; Hasegawa M; Masuda-Suzukake M; Mann DM; Allsop D
Sci Rep; 2013; 3():2540. PubMed ID: 23985836
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in Parkinson's disease: focus on plasma α-synuclein.
Caranci G; Piscopo P; Rivabene R; Traficante A; Riozzi B; Castellano AE; Ruggieri S; Vanacore N; Confaloni A
J Neural Transm (Vienna); 2013 Aug; 120(8):1209-15. PubMed ID: 23328951
[TBL] [Abstract][Full Text] [Related]
11. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control.
Lin WC; Lu CH; Chiu PY; Yang SY
Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863
[TBL] [Abstract][Full Text] [Related]
12. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.
Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J
Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson's disease.
Shu H; Zhang P; Gu L
Acta Neurol Belg; 2024 Jun; 124(3):831-842. PubMed ID: 38170418
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms.
Petricca L; Chiki N; Hanna-El-Daher L; Aeschbach L; Burai R; Stoops E; Fares MB; Lashuel HA
J Parkinsons Dis; 2022; 12(5):1449-1462. PubMed ID: 35527570
[TBL] [Abstract][Full Text] [Related]
16. Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration.
Schaeffer E; Kluge A; Schulte C; Deuschle C; Bunk J; Welzel J; Maetzler W; Berg D
J Parkinsons Dis; 2024; 14(4):667-679. PubMed ID: 38669557
[TBL] [Abstract][Full Text] [Related]
17. Potential Exosome Biomarkers for Parkinson's Disease Diagnosis: A Systematic Review and Meta-Analysis.
Kim KY; Shin KY; Chang KA
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791346
[TBL] [Abstract][Full Text] [Related]
18. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.
Shi M; Zabetian CP; Hancock AM; Ginghina C; Hong Z; Yearout D; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Leverenz JB; Zhang J
Neurosci Lett; 2010 Aug; 480(1):78-82. PubMed ID: 20540987
[TBL] [Abstract][Full Text] [Related]
19. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.
Si X; Tian J; Chen Y; Yan Y; Pu J; Zhang B
Neuroscience; 2019 Aug; 413():308-316. PubMed ID: 31102760
[TBL] [Abstract][Full Text] [Related]
20. Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease.
Emmanouilidou E; Papagiannakis N; Kouloulia S; Galaziou A; Antonellou R; Papadimitriou D; Athanasiadou A; Bozi M; Koros C; Maniati M; Vekrellis K; Ioannou PC; Stefanis L
Parkinsonism Relat Disord; 2020 Apr; 73():35-40. PubMed ID: 32234683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
